Fig. 1: Characterization in vitro of 4T1 murine mammary carcinoma cells response to incubation with TLR5 agonists.
From: TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy
4T1 cells stably expressing pκB5:IκBαFLuc were stimulated with the indicated ligand at t = 0 and bioluminescence activity imaged every 5 min for 4 h. Data are displayed as normalized photon flux values (average fold-initial, fold-vehicle). a 4T1 cells stably expressing pκB5:IκBαFLuc were treated with increasing flagellin concentrations: 1 ng/ml (n = 7), 10 ng/ml (n = 2), 50 ng/ml (n = 2), 100 ng/ml (n = 7), 500 ng/ml (n = 7), 750 ng/ml (n = 2), 1 μg/ml (n = 7), 2.5 μg/ml (n = 7), 3 μg/ml (n = 5), 4 μg/ml (n = 5), 5 μg/ml (n = 7), 7.5 μg/ml (n = 5), 10 μg/ml (n = 7), and TNFα 20 ng/ml (n = 7). Error bars represent S.E.M. for the indicated number of independent experiments. b 4T1 cells stably expressing pκB5:IκBαFLuc were treated with increasing CBLB502 concentrations: 0.1 ng/ml (n = 3), 0.5 ng/ml (n = 3), 1 ng/ml (n = 3) 1.5 ng/ml (n = 3), 2.5 ng/ml (n = 3), 5 ng/ml (n = 3), 10 ng/ml (n = 3), 25 ng/ml (n = 3), 100 ng/ml (n = 3), 1 μg/ml (n = 3), and TNFα 20 ng/ml (n = 3). Error bars represent S.E.M. for the indicated number of independent experiments. c The half maximal effective concentration (EC50) of flagellin in 4T1 cells is >104 ng/mL in this model. d The half maximal effective concentration (EC50) of CBLB502 in 4T1 cells is approximately 3.1 ng/mL in this model.
